OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
16 apr 2010 - 07:26
Statutaire naam
OctoPlus N.V.
Titel
Improved tolerability profile Locteron confirmed by data presented at EASL
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO) announces that its licensee Biolex Therapeutics has presented yesterday, during the 45th International Liver Congress (EASL) in Austria, a late-breaker poster containing interim clinical results after 12 weeks of treatment with Locteron® from its EMPOWER Phase IIb clinical study.
Datum laatste update: 31 augustus 2025